{"title":"晚期肝癌对顺铂联合索拉非尼、尼沃单抗和PG2免疫调节注射液的令人印象深刻的反应：一例报告","authors":"Chung-Kuan W, Ping-Hsiu W, Hung-Chih L","doi":"10.4172/2165-7920.10001161","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is an aggressive tumor, and sorafenib is the only proven drug for treating advanced HCC with limited survival outcome. We present a case of severe right lower chest pain in a 54-year-old man. A computed tomography (CT) scan revealed liver cirrhosis and multiple HCCs with inferior vena cava invasion, regional nodal and right adrenal metastases, and hemoperitoneum. His hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level and alpha-fetoprotein (AFP) remained high even after transcutaneous arterial catheter embolization for ruptured HCCs. He received combination therapy of entecavir, sorafenib, nivolumab, cisplatin, and PG2 injection. The follow-up positron emission tomography-CT confirmed no tumor in the liver, and alpha-fetoprotein and HBV DNA titers showed a promising decrease. This novel combination had encouraging therapeutic effects for advanced HCCs, which decreased viral replication without side effects.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001161","citationCount":"1","resultStr":"{\"title\":\"Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report\",\"authors\":\"Chung-Kuan W, Ping-Hsiu W, Hung-Chih L\",\"doi\":\"10.4172/2165-7920.10001161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatocellular carcinoma (HCC) is an aggressive tumor, and sorafenib is the only proven drug for treating advanced HCC with limited survival outcome. We present a case of severe right lower chest pain in a 54-year-old man. A computed tomography (CT) scan revealed liver cirrhosis and multiple HCCs with inferior vena cava invasion, regional nodal and right adrenal metastases, and hemoperitoneum. His hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level and alpha-fetoprotein (AFP) remained high even after transcutaneous arterial catheter embolization for ruptured HCCs. He received combination therapy of entecavir, sorafenib, nivolumab, cisplatin, and PG2 injection. The follow-up positron emission tomography-CT confirmed no tumor in the liver, and alpha-fetoprotein and HBV DNA titers showed a promising decrease. This novel combination had encouraging therapeutic effects for advanced HCCs, which decreased viral replication without side effects.\",\"PeriodicalId\":73664,\"journal\":{\"name\":\"Journal of clinical case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4172/2165-7920.10001161\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2165-7920.10001161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7920.10001161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report
Hepatocellular carcinoma (HCC) is an aggressive tumor, and sorafenib is the only proven drug for treating advanced HCC with limited survival outcome. We present a case of severe right lower chest pain in a 54-year-old man. A computed tomography (CT) scan revealed liver cirrhosis and multiple HCCs with inferior vena cava invasion, regional nodal and right adrenal metastases, and hemoperitoneum. His hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level and alpha-fetoprotein (AFP) remained high even after transcutaneous arterial catheter embolization for ruptured HCCs. He received combination therapy of entecavir, sorafenib, nivolumab, cisplatin, and PG2 injection. The follow-up positron emission tomography-CT confirmed no tumor in the liver, and alpha-fetoprotein and HBV DNA titers showed a promising decrease. This novel combination had encouraging therapeutic effects for advanced HCCs, which decreased viral replication without side effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
